NanoViricides Awaits Regulatory Decision for Ebola Trial of NV-387 Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to commence a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo (DRC). The company has submitted an application to the local regulatory agency and secured financing to support the study, which targets the ongoing Ebola outbreak. Currently, no approved treatment or vaccine exists for the Bundibugyo strain, underscoring the urgency of this investigation.

According to the company, NV-387 is the only orally administered Ebola treatment candidate under consideration for clinical testing. Its broad-spectrum antiviral mechanism could offer significant advantages over infusion-based therapies, particularly in resource-limited outbreak settings where logistical challenges often hinder treatment delivery. NanoViricides noted that sufficient quantities of the drug are already in the DRC to support the planned study, pending regulatory approval.

The trial aims to evaluate the oral antiviral's efficacy and safety in response to the Bundibugyo ebolavirus outbreak. The DRC has faced repeated Ebola outbreaks, with the current one involving a strain that lacks specific countermeasures. The availability of an oral treatment could dramatically improve access and adherence, reducing the burden on healthcare systems during emergencies.

NanoViricides' lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID-19, influenza, MPOX, and measles. The company's nanoviricide technology, licensed from TheraCour Pharma, Inc., involves creating special purpose nanomaterials designed to target viruses directly. This platform has shown potential in preclinical studies for a range of viruses, positioning NV-387 as a versatile therapeutic option.

The company's focus on Ebola aligns with global health priorities, as outbreaks continue to emerge in Africa. The World Health Organization has emphasized the need for innovative treatments, especially for strains like Bundibugyo that lack approved therapies. If successful, NV-387 could become a critical tool in outbreak response, complementing existing vaccines and treatments for other Ebola strains.

NanoViricides also highlighted that the oral formulation could simplify dosing and reduce the need for cold chain storage, making it easier to deploy in remote areas. This is particularly relevant in the DRC, where infrastructure challenges often complicate medical interventions. The company's proactive steps, including pre-positioning drug supplies, demonstrate a commitment to rapid deployment once regulatory approval is granted.

Investors and public health officials will closely monitor the regulatory decision, as it could pave the way for broader testing of oral antivirals against emerging viral threats. The company's stock, listed on NYSE American under the ticker NNVC, has seen increased attention amid the announcement. For more information, visit the company's newsroom at https://ibn.fm/NNVC.

This development underscores the importance of innovative antiviral strategies in addressing global health emergencies. NanoViricides continues to advance its pipeline, with NV-387 at the forefront of its efforts to combat viral diseases that pose significant public health risks.